Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 10/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17275374 | 1.00 | CA1 (0.44) | CA1CA2CA7HCAR2KEAP1 | |
| SCHEMBL31449996 | 1.00 | CA1 (0.44) | CA1CA2CA7HCAR2KEAP1 | |
| SCHEMBL384007 | 1.00 | CA1 (0.44) | CA1CA2CA7HCAR2KEAP1 | |
| SCHEMBL17275373 | 1.00 | CA1 (0.44) | CA1CA2CA7HCAR2KEAP1 | |
| SCHEMBL17275371 | 1.00 | CA1 (0.44) | CA1CA2CA7HCAR2KEAP1 | |
| SCHEMBL20326329 | 0.84 | CA1 (0.45) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL31450038 | 0.84 | CA1 (0.45) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL20334633 | 0.84 | CA1 (0.45) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL3096574 | 0.84 | CA1 (0.45) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL3096580 | 0.84 | CA1 (0.45) | CA1CA2CA7CTSKCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20240317777-A1 | NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2024178335-A2 | NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023004376-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-8101588-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2289893-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2011-03-02 | — | — | EP | disclosed |
| US-7723340-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | PHARMACOPEIA, LLC | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | TPMT, MGMT, HPRT1 | CA1 3051/4885CA2 2404/4885CA7 2815/4885 |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | CA1 4347/4885CA2 3649/4885CA7 3489/4885 |
| US-20240317777-A1 | NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK20, CDK3 | CA1 2902/4885CA2 2755/4885CA7 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.